From #ESCCongress 2026: Among individuals with left-sided infective endocarditis participating in the POET II trial, a response-tailored antibiotic strategy reduced treatment duration by 2 weeks.

👉️ buff.ly/hnd8aUv

#IDMed #CardioSky